Drug development

#Antibodies #Cancer research #Drug development #Research

Flow Eighteen38 reagent antibodies licensed for cancer research

Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More

#News

#Biotherapeutics #Drug candidates #Drug development #Therapeutics

Eli Lilly and MiNA Therapeutics saRNA research collaboration

Eli Lilly and Company and MiNA Therapeutics have created a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. MiNA will utilise its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key… Read More

#News

#Cell and gene therapy #Drug delivery #Drug development #Drug innovation #Life sciences

RoslinCT selected as vaccines and advanced therapies training centre

RoslinCT has been confirmed as a National Training Centre, part of the Department for Business, Energy & Industrial Strategy (BEIS) sponsored Advanced Therapies Skills Training Network (ATSTN) initiative. The organisation is the second National Training Centre confirmed as part of the ATSTN initiative, which was set up to develop vaccine… Read More

#News

#Data #Drug development #Drug repurposing #Drug research

In vitro drug interaction data critical in drug repurposing

Listen to this article on the DDW Podcast: In the wake of Covid-19 interest in repurposing a drug for a different indication to the one it was developed for has been high. Madison Knapp, Marketing Communications Specialist, and Dr. Brian Ogilvie, Vice President of Scientific Consulting, SEKISUI XenoTech offer… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Clinical trial #Drug development #MS

‘Mega-trial’ for progressive multiple sclerosis (MS) to launch

Octopus, a world-first mega-trial for progressive multiple sclerosis (MS), will launch in the UK later in 2021, according to the MS Society. It is a clinical trial that is said will transform the way treatments for progressive MS are tested and could deliver new options up to three times faster. Read More

#News

#Biologics / Biotechnology #Cell sequencing #DNA #Drug development #Drug discovery #Genome editing #Genome sequencing #Life sciences #Sequencing #Synthetic biology

The new synthesis: How synthetic DNA technology is changing drug discovery

Listen to this article on the DDW Podcast: Dr Tim Brears, CEO, Evonetix and Dr Raquel Sanches-Kuiper, Director of Biology, Evonetix explore applications of synthetic DNA in drug discovery and development, the benefits and limitations of current methods, and the opportunities offered by emerging DNA synthesis technologies. On 16… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biotechnology #Drug development #FDA #Research

The FDA expands lung-on-a-chip collaboration with CN Bio

The US. Food and Drug Administration (FDA) has extended its research collaboration with CN Bio for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using… Read More

#News

#Biotherapeutics #Cancer research #Drug development #Immuno-oncology #Pharmaceutical

Janssen seeks approval for refractory multiple myeloma drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More

#Cancer Research #News

#Data #Drug development #Drug discovery

China’s fast-track regulatory reforms not attracting non-Chinese companies

China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU and Japan to incentivise the development of drugs for unmet medical needs and serious conditions. However, only a few companies based outside of China have been granted priority review status by… Read More

#News

#Drug development #Drug discovery #Drug research #MS #Neuroscience #Stem cells

Mini 3-D brain models could speed up search for MS treatments

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be… Read More

#News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race… Read More

#Covid-19 #Exclusive Content #News

#Cell and gene therapy #Clinical research #Drug development

Update on gene therapy trial where patient suffered loss of vision

Adverum Biotechnologies has announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its Infinity clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomisation in one patient treated with a single intravitreal… Read More

#News

#Assay #Drug development #Drug toxicity #Preclinical development #Toxicology

Enhancing the predictability of drug toxicity and efficacy

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of… Read More

#Editor's Choice #News

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Biopharmaceuticals #Drug development #Life sciences

Awakn Life Sciences and Evotec start chemical entity programme

Awakn Life Sciences, a biotechnology company focused on addiction, has initiated a new chemical entity (NCE) development programme to strengthen its pipeline for the treatment of a broad range of addictions. The company has also announced the appointment of Evotec as its NCE research partner and the selection of… Read More

#News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News